Melola Discovery

← Melola Discovery

Jurnal SINTA 1

COVID-19 Vaccines: Current Status and Implication for Use in Indonesia

ACTA MEDICA INDONESIANA · Vol. 52 No. 4 (2020)

ISSN
2338-2732, 0125-9326
Terbit
2020-12-28
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in public health, economic and social stability—putting life globally on hold in 2020 and presumably a year more. Indonesia bears a heavy burden of the pandemic, counting the highest case prevalence and fatality rate in all of Southeast Asia. One hope remains in the groundbreaking universal effort in search of a vaccine against the causative virus SARS-CoV-2, which has shown success unparalleled in human vaccine development thus far. An array of modalities including novel techniques are being utilized as vaccine platforms, with the closest to phase III clinical trial completion being mRNA (manufactured by Moderna and BioNTech/Pfizer), inactivated virus (Sinovac, Sinopharm), viral vector (Oxford/AstraZeneca, Gamaleya, Janssen/Johnson&Johnson, CanSino), and protein subunit (Novavax). The vaccine produced by BioNTech/Pfizer has been deployed to the public as the first ever licensed COVID-19 vaccine. In this review, we will review all of these modalities on their safety and immunogenicity, phase II/III trial results of the nine vaccine candidates and current situation as of 29 December 2020, as well as the implication for use and distribution in Indonesia. COVID-19 vaccine progress, however, is moving exceedingly fast and new advances are unfolding on a daily basis, to which we hope an update to this review can be published in early 2021.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 313 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Rudi PutrantoAfiliasi tidak diketahui12
Teguh Harjono KarjadiAfiliasi tidak diketahui11
Pringgodigdo NugrohoAfiliasi tidak diketahui10
Eka GinanjarAfiliasi tidak diketahui10
Sally Aman NasutionAfiliasi tidak diketahui9
Hamzah ShatriAfiliasi tidak diketahui8
Agus Joko SusantoAfiliasi tidak diketahui8
Kuntjoro HarimurtiAfiliasi tidak diketahui7
Cissy KartasasmitaAfiliasi tidak diketahui7
Andi Makbul AmanAfiliasi tidak diketahui7
Ketut SuastikaAfiliasi tidak diketahui7
Chyntia Olivia Maurine JasirwanAfiliasi tidak diketahui6
Dyah PurnamasariAfiliasi tidak diketahui6
Cleopas Martin RumendeAfiliasi tidak diketahui5
Ikhwan RinaldiAfiliasi tidak diketahui4
Siti SetiatiAfiliasi tidak diketahui4
Nia KurniatiAfiliasi tidak diketahui3
Juferdy KurniawanAfiliasi tidak diketahui3
Andhika RachmanAfiliasi tidak diketahui3
Lugyanti SukrismanAfiliasi tidak diketahui3
Rudy HidayatAfiliasi tidak diketahui3
Robert SintoAfiliasi tidak diketahui3
Cleopas M RumendeAfiliasi tidak diketahui2
Erni J NelwanAfiliasi tidak diketahui2
Adityo SusiloAfiliasi tidak diketahui2
Raden Irawati IsmailAfiliasi tidak diketahui2
Simon SalimAfiliasi tidak diketahui2
Nurul Inayah RahmaniAfiliasi tidak diketahui2
Pradana SoewondoAfiliasi tidak diketahui2
Fera IbrahimAfiliasi tidak diketahui2
Nafrialdi NafrialdiAfiliasi tidak diketahui2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">COVID-19 Vaccines: Current Status and Implication for Use in Indonesia</dc:title>
	<dc:creator>Ophinni, Youdiil</dc:creator>
	<dc:creator>Hasibuan, Anshari Saifuddin</dc:creator>
	<dc:creator>Widhani, Alvina</dc:creator>
	<dc:creator>Maria, Suzy</dc:creator>
	<dc:creator>Koesnoe, Sukamto</dc:creator>
	<dc:creator>Yunihastuti, Evy</dc:creator>
	<dc:creator>Karjadi, Teguh H</dc:creator>
	<dc:creator>Rengganis, Iris</dc:creator>
	<dc:creator>Djauzi, Samsuridjal</dc:creator>
	<dc:subject xml:lang="en-US">vaccine</dc:subject>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">Indonesia</dc:subject>
	<dc:description xml:lang="en-US">The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in public health, economic and social stability—putting life globally on hold in 2020 and presumably a year more. Indonesia bears a heavy burden of the pandemic, counting the highest case prevalence and fatality rate in all of Southeast Asia. One hope remains in the groundbreaking universal effort in search of a vaccine against the causative virus SARS-CoV-2, which has shown success unparalleled in human vaccine development thus far. An array of modalities including novel techniques are being utilized as vaccine platforms, with the closest to phase III clinical trial completion being mRNA (manufactured by Moderna and BioNTech/Pfizer), inactivated virus (Sinovac, Sinopharm), viral vector (Oxford/AstraZeneca, Gamaleya, Janssen/Johnson&amp;amp;Johnson, CanSino), and protein subunit (Novavax). The vaccine produced by BioNTech/Pfizer has been deployed to the public as the first ever licensed COVID-19 vaccine. In this review, we will review all of these modalities on their safety and immunogenicity, phase II/III trial results of the nine vaccine candidates and current situation as of 29 December 2020, as well as the implication for use and distribution in Indonesia. COVID-19 vaccine progress, however, is moving exceedingly fast and new advances are unfolding on a daily basis, to which we hope an update to this review can be published in early 2021.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2020-12-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/1648</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 52 No. 4 (2020): Acta Medica Indonesiana; 388</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/1648/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2020 Acta Medica Indonesiana</dc:rights>
</oai_dc:dc>